Clinical Trials for Mixed-Type Liposarcoma
There is currently 1 ongoing clinical trial for patients with mixed-type liposarcoma. This trial is investigating a combination treatment approach for patients whose cancer has spread or not responded to previous treatments. The study is being conducted in Germany and compares standard chemotherapy alone with a combination of standard chemotherapy plus an experimental drug designed to concentrate the treatment inside tumors.
Clinical trial locations
Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment
This clinical trial is designed for patients with soft tissue sarcoma whose cancer has spread to other parts of the body or who did not respond well to previous treatments. The study compares two different treatment approaches to determine which one helps keep the cancer under control for a longer period of time.
Main inclusion criteria: The study accepts adults between 18 and 75 years of age who have been diagnosed with advanced or metastatic soft-tissue sarcoma, including mixed-type liposarcoma. Participants must have high-grade cancer (grade 2-3) that either did not respond to previous anthracycline treatment or where anthracycline medications cannot be used for medical reasons. The tumor must test positive for a specific protein marker called CD13 with a score of 1 or higher. Patients must have at least one measurable tumor that has not been previously treated with radiation and have a life expectancy of at least 3 months. Women who can become pregnant must use effective birth control during the study and for 3 months afterward, while men must use birth control methods for 5 months after the last treatment.
Main exclusion criteria: The study cannot accept patients who are pregnant or breastfeeding, those who have previously been treated with trabectedin, or patients with severe heart, liver, or kidney problems. People with active uncontrolled infections, other active cancers requiring treatment, or known allergic reactions to the study medications are also excluded. Patients who have participated in another clinical trial within the past 30 days or who test negative for the CD13 protein marker cannot join this study.
Focus and goal: The main goal of this trial is to determine whether combining trabectedin with an experimental drug called tTF-NGR is more effective than using trabectedin alone. Participants are randomly assigned to receive either trabectedin by itself or trabectedin together with tTF-NGR. Both medications are given through an intravenous infusion directly into the bloodstream. Treatment continues for up to 360 days, with regular medical examinations and imaging tests performed to monitor how the cancer responds. The study is expected to continue until March 2029.
Investigational drugs: The study uses trabectedin, a cancer medication that interferes with cancer cell growth and division, and tTF-NGR, an experimental drug designed to help trap the chemotherapy medication inside the tumor. The tTF-NGR targets blood vessels in tumors and aims to keep the medication concentrated where it is needed most, potentially making the cancer treatment more effective. Trabectedin is a marine-derived medication that works by binding to DNA and interfering with processes that allow cancer cells to grow and divide.
Summary
Currently, there is one clinical trial available for patients with mixed-type liposarcoma, located in Germany. This trial focuses on patients whose disease has spread or not responded to initial treatment with anthracycline-based chemotherapy. The study investigates whether adding an experimental drug (tTF-NGR) to standard trabectedin chemotherapy can improve outcomes compared to trabectedin alone. A key requirement for participation is that the tumor must test positive for the CD13 protein marker, which is determined through laboratory testing. The trial represents an important research effort for patients who have limited treatment options after first-line therapy has failed.
